TP53 and cancer: Based on the findings that wild-type (WT) p53 represses SLC7A11 expression and p53 deficiency promotes SLC7A11 expression in cancer cells (Jiang et al., 2015), one would expect that p53 mutants with oncogenic functions, similar to p53 deficiency, should promote SLC7A11 expression.